Analysts Set Aquestive Therapeutics, Inc. (NASDAQ:AQST) Price Target at $8.50

Aquestive Therapeutics, Inc. (NASDAQ:AQST) has received a consensus recommendation of “Buy” from the seven analysts that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, four have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $8.50.

Several research analysts have commented on AQST shares. Oppenheimer began coverage on Aquestive Therapeutics in a research note on Friday, April 24th. They issued an “outperform” rating and a $8.00 target price for the company. Wall Street Zen cut Aquestive Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Aquestive Therapeutics in a report on Friday, July 17th.

Insiders Place Their Bets

In related news, Director Julie Krop sold 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $5.02, for a total transaction of $125,500.00. Following the sale, the director owned 25,000 shares of the company’s stock, valued at approximately $125,500. This represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.81% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. NewEdge Advisors LLC bought a new stake in Aquestive Therapeutics during the third quarter valued at $28,000. BNP Paribas Financial Markets increased its stake in Aquestive Therapeutics by 78.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company’s stock worth $31,000 after acquiring an additional 4,134 shares during the last quarter. Modern Wealth Management LLC purchased a new stake in shares of Aquestive Therapeutics in the 2nd quarter valued at about $33,000. Elevation Point Wealth Partners LLC purchased a new stake in shares of Aquestive Therapeutics in the 1st quarter valued at about $42,000. Finally, ADAR1 Capital Management LLC boosted its position in shares of Aquestive Therapeutics by 103.9% during the 1st quarter. ADAR1 Capital Management LLC now owns 10,000 shares of the company’s stock valued at $42,000 after acquiring an additional 264,000 shares during the last quarter. Institutional investors own 32.45% of the company’s stock.

Aquestive Therapeutics Price Performance

Shares of AQST stock opened at $4.59 on Thursday. The company’s fifty day simple moving average is $4.16 and its two-hundred day simple moving average is $4.11. Aquestive Therapeutics has a 1 year low of $2.93 and a 1 year high of $7.55. The stock has a market capitalization of $576.09 million, a price-to-earnings ratio of -7.06 and a beta of 1.49.

Aquestive Therapeutics (NASDAQ:AQST) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.08). The firm had revenue of $13.82 million during the quarter, compared to analysts’ expectations of $11.42 million. Equities research analysts anticipate that Aquestive Therapeutics will post -0.45 EPS for the current year.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.